Comparative Pharmacology
Head-to-head clinical analysis: ALOCRIL versus NEDOCROMIL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOCRIL versus NEDOCROMIL SODIUM.
ALOCRIL vs NEDOCROMIL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mast cell stabilizer that inhibits the release of inflammatory mediators (e.g., histamine, leukotrienes) from conjunctival mast cells. Also inhibits eosinophil chemotaxis and activation.
Nedocromil sodium is a mast cell stabilizer that inhibits the release of inflammatory mediators (e.g., histamine, leukotrienes) from mast cells and other inflammatory cells. It also reduces sensory nerve activation and inhibits eosinophil chemotaxis.
2 drops in each eye four times daily; ophthalmic route.
2 inhalations (2 mg per inhalation) four times daily via metered-dose inhaler, or 2 inhalations (4 mg per inhalation) twice daily via dry powder inhaler.
None Documented
None Documented
8.6 hours (terminal elimination half-life in healthy adults; may be prolonged in renal impairment, e.g., up to 18 hours in patients with severe renal dysfunction).
Terminal elimination half-life is approximately 2 hours; clinically, this supports twice-daily dosing for sustained effect.
Renal (primarily unchanged drug; approximately 50-60% excreted unchanged in urine within 48 hours). Biliary/fecal elimination accounts for <10%.
Primarily renal excretion of unchanged drug; approximately 70% excreted in urine and 30% in feces via biliary elimination.
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer